1 TITLE

2 ENDOTHELIAL CELL-DERIVED EXTRACELLULAR VESICLES ELICIT
 3 NEUTROPHIL DEPLOYMENT FROM THE SPLEEN FOLLOWING ACUTE
 4 MYOCARDIAL INFARCTION

- 5
- 6 One Sentence Summary

7 Extracellular vesicles mediate neutrophil mobilisation from the spleen following acute
8 myocardial infarction.

9

#### 10 Authors

Naveed Akbar<sup>1</sup>, Adam T. Braithwaite<sup>1</sup>, Emma M. Corr<sup>2</sup>, Graeme J. Koelwyn<sup>2</sup>, Coen 11 van Solingen<sup>2</sup>, Clément Cochain<sup>3</sup>, Antoine-Emmanuel Saliba<sup>4</sup>, Alastair Corbin<sup>5</sup>, 12 Daniela Pezzolla<sup>1</sup>, Laurienne Edgar<sup>1</sup>, Mala Gunadasa-Rohling<sup>6</sup>, Abhirup Banerjee<sup>1</sup>, 13 Daan Paget<sup>1</sup>, Charlotte Lee<sup>1</sup>, Eleanor Hogg<sup>1</sup>, Adam Costin<sup>7</sup>, Raman Dhaliwal<sup>7</sup>, Errin 14 Johnson<sup>7</sup>, Thomas Krausgruber<sup>8</sup>, Joey Riepsaame<sup>7</sup>, Genevieve E. Melling<sup>9</sup>, 15 Mayooran Shanmuganathan<sup>1, 10, 11</sup>, Oxford Acute Myocardial Infarction Study 16 (OxAMI)<sup>1, 10, 11</sup>, Christoph Bock<sup>8,12</sup>, David R. F Carter<sup>9</sup>, Keith M. Channon<sup>1, 10, 11</sup>, Paul 17 R. Riley<sup>6</sup>, Irina A. Udalova<sup>5</sup>, Kathryn J. Moore<sup>2</sup>, Daniel Anthony<sup>13</sup>, Robin P. 18 Choudhurv<sup>1, 10, 11</sup> 19

20

# 21 Affiliations

<sup>1</sup>Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of
 Oxford.

<sup>24</sup> <sup>2</sup>NYU Cardiovascular Research Center, Department of Medicine, Division of

25 Cardiology, School of Medicine, New York University School of Medicine<sup>-</sup>

- <sup>26</sup> <sup>3</sup>Comprehensive Heart Failure Center, University Hospital Wurzburg, Germany
- <sup>4</sup>Helmholtz Institute for RNA-based Infection Research (HIRI), Helmholtz-Center for
- 28 Infection Research (HZI)
- <sup>5</sup>Kennedy Institute of Rheumatology, University of Oxford.
- <sup>6</sup>Department of Physiology, Anatomy and Genetics, University of Oxford.
- <sup>31</sup> <sup>7</sup>Sir William Dunn School of Pathology, University of Oxford.
- <sup>32</sup> <sup>8</sup>CeMM Research Center for Molecular Medicine of the Austrian Academy of
- 33 Sciences, Vienna, Austria.
- <sup>9</sup>Department of Biological and Medical Sciences, Oxford Brookes University.
- <sup>10</sup>The OxAMI Study is detailed in the Supplemental Acknowledgments.
- <sup>11</sup>Acute Vascular Imaging Centre, Radcliffe Department of Medicine, University of
- 37 Oxford.
- <sup>12</sup>Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
- <sup>13</sup>Department of Pharmacology, University of Oxford.
- 40

# 41 Corresponding Author

- 42 Professor Robin Choudhury
- 43 Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of
- 44 Oxford.
- 45 <u>robin.choudhury@cardiov.ox.ac.uk</u>

#### 46 Abstract

47 Acute myocardial infarction rapidly increases blood neutrophils (<2 hours). Release 48 of neutrophils from bone marrow, in response to chemokine elevation, has been 49 considered their source, but chemokine levels peak up to 24 hours after injury, and 50 after neutrophil elevation. This suggests that additional non chemokine-dependent processes may be involved. Endothelial cell (EC) activation promotes the rapid (<30 51 minutes) release of extracellular vesicles (EVs), which are enriched in vascular cell 52 53 adhesion molecule-1 (VCAM-1) and miRNA-126, and are thus a potential 54 mechanism for communicating with remote tissues.

Here, we show that injury to the myocardium rapidly mobilises neutrophils from the 55 56 spleen to peripheral blood and induces their transcriptional activation prior to their 57 arrival at injured tissue. Ischemic myocardium leads to the generation and release of 58 EC-derived-EVs bearing VCAM-1. EC-EV delivery to the spleen alters inflammatory 59 gene and chemokine protein expression, and mobilises neutrophils to peripheral 60 blood. Using CRISPR/Cas9 genome editing we generated VCAM-1-deficient EV and 61 showed that its deletion removed the ability of EC-EV to provoke the mobilisation of 62 neutrophils. Furthermore, inhibition of miRNA-126 in vivo reduced myocardial infarction size in a mouse model. Our findings show a novel mechanism for the rapid 63 mobilisation of neutrophils to peripheral blood from a splenic reserve, independent of 64 65 classical chemokine signalling, and establish a proof of concept for functional 66 manipulation of EV-communications through genetic alteration of parent cells.

67

## 68 Introduction

69 Acute myocardial infarction (AMI) is a substantial sterile injury that leads to a rapid 70 increase in peripheral blood neutrophils (1-5). Elevated peripheral blood neutrophil 71 number post-AMI correlates with the extent of myocardial injury, degree of cardiac dysfunction, and mortality (1-3). Defective neutrophil removal enhances susceptibility 72 to cardiac rupture (6) and inhibition of neutrophil recruitment in AMI reduces infarct 73 size (1), but antibody depletion of neutrophils prior to AMI increases infarct size, 74 75 enhances fibrosis and lowers the number of M2 macrophages in the healing 76 myocardium (1, 7). These findings suggest a complex role for neutrophils in the 77 contexts of myocardial ischaemic injury and repair.

The bone marrow is the primary site for granulopoiesis (8, 9) and has been regarded 78 79 as the principal source of neutrophils that are mobilised to peripheral blood after 80 injury (4, 10). Mature neutrophils are held in large numbers in the haemopoietic 81 cords, separated from the blood by the sinusoidal endothelium (11). In the current 82 paradigm, these cells are retained in the marrow by the interaction of CXCR4 and 83 CXCL12 (stromal cell derived factor (SDF-1 $\alpha$ )) (12) and mobilised in response to 84 soluble factors. Intravascular injection of a range of chemotactic factors, including 85 leukotriene B4, C5a, interleukin-8 (IL-8) (13), CXCL chemokines (12, 14) and 86 granulocyte-colony stimulating factor (G-CSF) (15, 16) can drive the rapid 87 mobilisation of neutrophils across the sinusoidal endothelium. However, numerous 88 strands of evidence question whether chemokines derived from injured tissues are 89 responsible for very early neutrophil mobilisation in vivo. Intra-cardiac mRNA levels 90 for cytokines peak 12 hours after injury (17) and pro-inflammatory proteins are very 91 modestly elevated in coronary sinus following reperfusion therapy in AMI (18, 19). 92 Furthermore, in vivo blood chemokine profiles peak 24 hours post-AMI and do not

precede the rise in blood neutrophil counts in humans or mice, which occurs within 2
hours in mice following injury (*1, 20*). Moreover, a putative source of chemokine
generation in the acutely ischemic myocardium prior to neutrophil infiltration has not
been identified.

These observations suggest that neutrophils may be mobilised from alternative reserves following injury and by mechanisms that are not dependent on chemokines. One possible source is extramedullary haematopoiesis in the spleen (*21*) from where neutrophils are mobilised to peripheral blood following bacterial infection (*22*). By analogy, it is known that monocytes are deployed from a splenic reserve and not from the bone marrow following sterile injury in mice (*23*), and that this can be driven by extracellular vesicles (EVs) that are derived from the vascular endothelium (*24*).

104 EVs are membrane-enclosed envelopes (25) that are actively secreted by many cell 105 types (26-28). These vesicles bear bioactive cargo that includes proteins and 106 microRNAs (miRNAs), which are derived from the parent cell. EV can alter the 107 biological function and cellular status of cells locally (29) and remotely following 108 liberation into the blood (30). Endothelial cell (EC) derived-EVs bearing vascular cell 109 adhesion molecule-1 (VCAM-1) are elevated in the blood following AMI (24, 29) and 110 have a role in the mobilisation and transcriptional programming of splenic monocytes 111 in AMI (24).

Here, we sought to establish whether EC-EVs contribute to the mobilisation and programming of neutrophils and, if so, through which of their component parts. We hypothesised that EC-EVs released during ischaemia would localise to neutrophils in remote reserves in a process mediated by VCAM-1, which has been shown to bind to neutrophils via surface integrins (*31*). Furthermore, we reasoned that once localised to neutrophils in reserve pools, EC-EV miRNA cargo could induce functionally relevant transcriptional programmes in those target tissues and cells prior to recruitment to the injured myocardium. An understanding of these mechanisms would immediately suggest possibilities for cell-selective immunomodulatory interventions that are relevant in AMI and, potentially, other pathologies with an inflammatory component.

Accordingly, we investigated changes in the number and composition of EC-EVs in mice and humans in the context of AMI, examined their tissue distribution and effects on cell mobilisation and programming *in vitro* and *in vivo*. We used bioinformatics techniques to identify plausible bioactive candidates and evaluated their functional significance experimentally *in vivo* using antagomir and gene editing approaches.

#### 128 **Results**

#### 129 Plasma neutrophil number correlates with the extent of AMI

During acute ST-segment-elevation AMI (STEMI) in human patients (median time from onset of symptoms 3 hours) peripheral blood neutrophil number at the time of presentation correlated with the extent of ischaemic injury, as determined by oedema estimation on T2-weighted magnetic resonance imaging (MRI) images obtained within 48 hours of AMI ( $R^2 = 0.365$ , P = 0.017) (**Figure 1A**) and with final infarct size, determined by late gadolinium enhancement (LGE) MRI 6 months post-AMI ( $R^2$ =0.507, P=0.003) (**Figure 1B**).

137

#### 138 AMI mobilises neutrophils from the spleen

139 This rapid increase in peripheral blood neutrophils would be consistent with 140 mobilisation from an existing reserve. To determine the source of neutrophil 141 mobilisation in the immediate hours post-AMI we performed left anterior descending 142 (LAD) artery ligation in a mouse model of AMI and analysed cell populations from multiple tissue sources, 2 hours after AMI, by flow cytometry (Figure 1C). AMI 143 induced a 6.3-fold (P<0.01) increase in peripheral blood neutrophils (Live, CD45<sup>+</sup>, 144 CD11b<sup>+</sup>, Ly6G<sup>+</sup>) and simultaneously lowered splenic-neutrophil number by 0.7-fold 145 146 (P<0.001) (Figure 1D). As described previously, to obtain an indication of the 147 mobilisation between reserves, we calculated a neutrophil mobilisation ratio (24) 148 (peripheral blood neutrophils/ splenic [or bone marrow] neutrophils) and found an increase in splenic neutrophil-mobilisation (8.5-fold) (P<0.01), but no alteration in 149 150 bone marrow neutrophil number relative to control animals. There was no alteration 151 in CD62L/L-selectin (which is shed during neutrophil activation) in mobilised

peripheral blood neutrophils (**Figure 1E**). At this very early time point (2 hours post-AMI), we found no differences in LyC6<sup>high</sup> monocyte number in the peripheral blood or spleen, indicating that neutrophils mobilise from the spleen prior to splenicmonocyte mobilisation (*23*) (**Figure 1F**).

156

#### 157 Plasma EVs correlate with the extent of injury and neutrophil count in AMI

158 Following AMI EC-EVs are significantly augmented in peripheral blood, with plasma-EVs showing enrichment for miRNA-126 and the integrin VCAM-1 (24, 29). In 159 160 agreement with our previous findings, patients with AMI had significantly more plasma EVs at time of presentation (24.3 x 10  $^{8}$  ± 25.7 EV / mL) versus a 6 month 161 follow-up measurement (11.0 x 10  $^{8}$  ± 12.5 EV / mL, P<0.01) but they exhibited a 162 163 similar EV size distribution profile, with a significant elevation in EVs in the size 164 range 100-200 nm diameter (Figure 2A/B). Plasma EV number at presentation was significantly correlated with the extent of ischaemic injury as determined by T2-165 weighted MRI (R<sup>2</sup>=0.459, P=0.006) (Figure 2C) and with the extent of myocardial 166 scarring as determined by LGE at 6 months post-AMI (R<sup>2</sup>=0.423, P=0.009) (Figure 167 2D). We also found a highly significant relationship between plasma-EV number and 168 peripheral blood neutrophil number ( $R^2$ =0.753, P<0.001) at time of presentation 169 170 (Figure 2E), consistent with a possible role for plasma-EVs in neutrophil mobilisation 171 post-AMI.

172

# 173 EC-EVs are enriched for miRNA-126

174 In AMI, the total EV pool is enriched for EVs bearing VCAM-1 (*24*). Endothelial cells 175 are activated in AMI (*32*) and express VCAM-1 in response to ischaemia *in vivo* (*33*)

176 and to pro-inflammatory cytokines such as tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ) in vitro 177 (34). In order to probe the function of EVs-derived exclusively from activated 178 endothelial cells we studied primary human umbilical cord vein endothelial cells in vitro. Compared with basal conditions, treatment of endothelial cells with pro-179 180 inflammatory TNF-α activated endothelial cells as evidenced by enhanced VCAM-1 181 protein expression (P<0.001) (Figure 3 A) and increased EV production (P<0.001) (Figure 3B/C), with a significant increase in small EVs, of similar size range (100-182 183 200 nm) to those found to increase in patients with AMI. EC-EVs displayed typical 184 EV morphology (Figure 3D/E), the EV-protein marker CD9 (Figure 3F) and were 185 positive for endothelial nitric oxide synthase (eNOS). EV-depleted cell culture 186 supernatants and cell culture media that had not been exposed to cells were negative for CD9 and eNOS, confirming robust EC-EV generation and isolation. EC-187 188 EV preparations were negative for histone and mitochondrial markers of cellular 189 contamination, which were readily detected in endothelial cell pellets but not in 190 isolated EC-EVs or in EV-depleted cell culture supernatants (Figure 3F).

EC-EVs derived from pro-inflammatory stimulations show significant enrichment for miRNA-126-3p (P<0.01) (**Figure 3G**) and miRNA-126-5p (P<0.01) (**Figure 3H**), consistent with previous observations of changes in miRNA, measured in the unselected EV pool, following AMI (*24*).

195

## 196 miRNA-126-mRNA targets cluster selectively in neutrophil motility pathways

To explore the potential role of EC-EV-miRNA-126 we employed *in silico* bioinformatics techniques. We curated miRNA-126 putative mRNA target genes from 3 different miRNA-mRNA target prediction databases for human and the mouse. Our

curated lists comprised targets from TargetScanHuman, TargetScanMouse (*35*),
miRWalk (*36*) and miRDB (*37*).

202 We determined whether the mRNAs putatively regulated by miRNA-126 for the 203 human, mouse or the overlap gene set (targeted in both the human and mouse) 204 (Figure 3I/3J and Supplementary Table 1/2) were present in Gene Ontology (GO) 205 terms for neutrophil function. miRNA-126-putative-mRNA targets were significantly 206 overrepresented when compared by Fisher's exact test to neutrophil pathway GO terms for neutrophil migration (GO: GO1990266) in the human (P < 0.001), the 207 208 mouse (P<0.001) and the overlap gene set (P<0.001) (Supplementary Table 3). Similarly, miRNA-126-putative-mRNA targets were significantly overrepresented 209 210 when compared to the neutrophil pathway GO term for neutrophil chemotaxis (GO: 211 GO0030593) in the human (P < 0.001), the mouse (P < 0.001) and the overlap gene 212 set (P<0.001) (Supplementary Table 3). Whereas, other neutrophil GO terms such 213 as neutrophil mediated killing of a fungus (GO: GO0070947), neutrophil clearance 214 (GO: GO0097350) and regulation of neutrophil mediated cytotoxicity (GO: 0070948) 215 were not enriched (Supplementary Table 3), suggesting a possible role for EC-EV-216 miRNA-126 in orchestrating processes related to neutrophil mobilisation post-AMI.

217

## 218 AMI alters neutrophil transcriptomes

219 To determine whether neutrophil transcriptomes are altered post-AMI we obtained 220 peripheral blood neutrophils from newly recruited patients presenting with STEMI (N 221 = 3) and non-STEMI (NSTEMI) control patients (N = 3) at time of presentation and matched-control samples one month later. STEMI patients had a greater number of 222 223 differentially expressed genes at time of presentation vs NSTEMI control patients 224 (STEMI 933 genes vs NSTEMI 8 genes) (Figure 4A-C). Differentially expressed 225 neutrophil transcriptomes in STEMI patients were determined by Gene Set 226 Enrichment Analysis (GSEA) to be positively enriched at time of presentation for 227 inflammatory pathways, including TNF- $\alpha$  signalling via NF- $\kappa$ B (P<0.001), 228 inflammatory response (P<0.001) and interleukin-6 (IL-6) signalling via JAK-STAT3 229 (P<0.001) (**Figure 4D**).

230 To further understand the potential target pathways for the differentially enriched 231 genes in blood neutrophils following AMI we used GO term enrichment analysis and 232 ranked by false discovery rate (FDR)-adjusted p-values. GO analysis showed that 233 differentially expressed neutrophil genes at the time of presentation favoured 234 pathways for signal recognition particle (SRP)-dependent co-translational protein 235 targeting to membrane (GO:0006614) (P<0.001) and co-translational protein 236 targeting to membrane (GO:0006613) (P<0.001) (Supplementary Table 4). 237 Similarly, we used Reactome pathway analysis (38) to further explore target 238 pathways for the differentially enrichment genes at the time of presentation and 239 found SRP-dependent co-translational protein targeting to membrane (R-HSA-240 1799339) (P<0.001) and neutrophil degranulation (R-HSA-6798695) (P<0.001) to be 241 significantly enriched (Supplementary Table 4).

242 Next, we used single cell (sc)-RNA-sequencing data to determine whether neutrophil 243 populations in the peripheral blood of mice subjected to AMI exhibited similar 244 transcriptomic alterations prior to recruitment to the heart. We found differential 245 enrichment in neutrophil populations in the blood following AMI (39), which favoured 246 GO terms for neutrophil aggregation (GO:0070488) (Supplementary Table 5 and 6) 247 (P<0.05), platelet activation (GO:0030168) (P<0.001) (Supplementary Table 7) and 248 Reactome pathways for SRP-dependent co-translational protein targeting to 249 membrane (R-HSA-1799339) (P<0.001) (Supplementary Table 5 and 6) (P<0.001) 250 and platelet activation, signalling and aggregation (R-HSA-76002) (P<0.001) 251 (Supplementary Table 7).

252 These analyses show that in both human and mouse neutrophils transcription is 253 differentially regulated in AMI. We further explored commonality between the human 254 and the mouse transcriptome response following AMI using GO terms (biological 255 process, molecular function and cellular component) and Reactome pathways 256 analysis. There were significant overlaps between the genes that are differentially 257 expressed following AMI in the blood of the human and the mouse (P<0.001) 258 (Supplementary Table 8) and significant similarity in target pathways between the 259 human and mouse (Supplementary Table 9), demonstrating that patterns of gene 260 expression are conserved and occur prior to recruitment to the injured heart. We 261 ranked the significant comparisons by size of their intersect and found that sc-RNA-262 sequencing mouse blood neutrophil populations shared 38% similarity (P<0.001) and 263 37% similarity (P<0.001), respectively, to target pathways in human neutrophils 264 following AMI (Supplementary Table 9).

265

# 266 miRNA-126-mRNA targets are overrepresented in neutrophil transcriptomes

#### 267 following AMI

268 Human miRNA-126-mRNA targets were significantly overrepresented in human 269 neutrophil transcriptomes at the time of injury (P<0.05) (Supplementary Table 10). There was no association between the differentially expressed genes in the mouse 270 271 blood neutrophil sc-RNA-sequencing populations and miRNA-126-mRNA targets 272 (Supplementary Table 10), but neutrophils within the myocardium displayed 273 differential enrichment for miRNA-126-mRNA targets (Supplementary Table 10). 274 There was significant enrichment for miRNA-126-mRNA targets from the human, 275 mouse and the overlap lists (P<0.001), consistent with a role for miRNA-126 in 276 regulating neutrophil gene expression following AMI.

To test the functional significance of these findings, we treated wild-type mice with an antagomiR for miRNA-126 (n = 5) or a scramble control (n = 7) prior to induction of experimental AMI to assess the role of miRNA-126 on infarct size (**Figure 4E**) and found a 12% reduction in infarct size in animals that received the miRNA-126 antagomir versus the scramble control (P<0.01) (**Figure 4F**).

282

#### 283 EC-EVs localise to the spleen

These accumulating data suggest that EC-EVs, enriched for miRNA-126 and VCAM-1 provide an 'ischaemia signal' to neutrophils in the spleen, resulting in mobilisation and transcriptional activation. Accordingly, we tested whether EC-EV localised to the spleen after intravenous injection and whether there were consequent alterations in neutrophil-associated chemokine gene and protein expression. Primary mouse and human endothelial cells release more EVs following inflammatory stimulation (*24*)

290 and hypoxia (40). In agreement with these data and our previous observations, 291 mouse sEND.1 endothelial cells produced EV under basal conditions and released 292 significantly more EVs after pro-inflammatory stimulation with TNF- $\alpha$  (P<0.001) 293 (**Figure 5A/B**) (24). We confirmed endothelial cell activation by TNF- $\alpha$  by probing for 294 VCAM-1 protein and found significantly more protein (P<0.001) (Figure 3C). EC-EVs 295 displayed typical EV morphology (Figure 5D/E), EV-protein markers ALIX, TSG101 296 and CD9 (Figure 5F) and were positive for eNOS and VCAM-1. EV-depleted cell 297 culture supernatants and cell culture media that had not been exposed to cells were 298 negative for ALIX, TSG101, CD9, eNOS and VCAM-1, confirming robust EC-EV 299 isolation. EC-EVs derived from pro-inflammatory stimulations showed significant 300 enrichment for miRNA-126-3p (P<0.001) (Figure 5G) and miRNA-126-5p (P<0.01) 301 (Figure 5H), indicating similarities in the EC-EV response between human and 302 mouse endothelial cells. We labelled the mouse EC-EV by transfection with non-303 mammalian miRNA-39, which belongs to C. elegans and allows quantitative tracing 304 of EVs in vivo (Figure 6A). This EC-EV labelling approach showed that EC-EVs 305 accumulated rapidly in the spleen and were detectable 2 hours, 6 hours (P<0.001) 306 and 24 hours (P<0.001) post-intravenous injection (Figure 6A).

307

# 308 EC-EVs alter chemokine and protein expression in the spleen

Informed by the earlier *in silico* studies suggesting regulation of neutrophil activation and motility by miRNA-126, we hypothesised that EC-EV localisation in the spleen would alter gene expression within spleen tissue, with a focus on CXC chemokine and cytokine activity.

EC-EVs induced significantly altered mRNA in expression for *Cxcr2, Itag4, Gapdh* (all, P<0.05), *II-1\beta, Cxcl1* (both, P<0.01), *Cxcr4 and II-6* (both, P<0.001) post-EC-EV injection (Figure 6B).

316 We further determined whether delivery of EC-EVs to the spleen altered chemokine 317 protein levels, including for the retention chemokine CXCL12 / SDF-1. In the same 318 mice we undertook a quantitative protein-detection array for 25 different proteins that 319 influence neutrophil function, including CXCL12 / SDF-1, CCL2 (41) and CCL3 (42), which are known miRNA-126-mRNA targets and CCL27/ CCL28, which are 320 321 predicted miRNA-126-mRNA targets. There were significant reductions in 6CKine/CCL21 (P<0.01), BLC/CXCL13 (P<0.05), chemerin/retinoic acid receptor 322 responder protein 2 (RARRES2) (P<0.01), IL-16 (P<0.05), MCP-5/CCL12 (P<0.05) 323 324 and CXCL12 / SDF-1. (P<0.05) (Figure 6C). These findings are consistent with a 325 role for EC-EV-miRNA-126 in silencing genes involved in cell retention.

326

#### 327 Endothelial cell derived EVs mobilise neutrophils from the spleen

328 Given the effects of the EC-EVs derived from TNF-a activated cells on gene 329 expression and silencing of retention chemokines, we injected EC-EVs, derived from 330 TNF- $\alpha$  activated endothelial cells, intravenously into healthy wild-type mice vs sham injection (Figure 7A). Flow cytometry (Live, CD45<sup>+</sup>, CD11b<sup>+</sup>, Ly6G<sup>+</sup>) showed that 331 332 EC-EVs significantly increased the number of circulating peripheral blood neutrophils (Figure 7B), and simultaneously lowered splenic-neutrophil numbers in the same 333 334 mice (Figure 7B), confirming splenic neutrophil mobilisation induced by EC-EV. Consistent with our observations in AMI we found that EC-EVs mediated greater 335 336 neutrophil mobilisation from the spleen (P<0.001) than from the bone marrow

(Figure 7C). As in the context of AMI, there was no alteration in CD62L/L-selectin
expression in blood neutrophils (Figure 7D).

339

## 340 EC-EV VCAM-1 mediates neutrophil mobilisation

341 Plasma EVs present VCAM-1 on their surface (Figure 8A) and the number of 342 VCAM-1 positive EVs increases after AMI (24). Similarly, endothelial cells in culture 343 produce EVs enriched for VCAM-1 following pro-inflammatory stimulation (Figure 344 5E). Given its well-established role in mediating interactions between activated 345 vascular endothelium and circulating leukocytes, we hypothesised that VCAM-1 on 346 EC-EVs might perform the converse role by mediating the capture of circulating EC-347 EVs by static neutrophils in the spleen. We used CRISPR-Cas9 base editing of 348 endothelial cells to produce VCAM-1 deficient EC-EVs by introducing a stop codon in 349 the VCAM-1 sequence. To confirm CRISPR-Cas9 editing of VCAM-1 from 350 endothelial cells we stimulated wild-type (WT) and VCAM-1 knock-out (KO) cells with 351 TNF- $\alpha$ . WT mouse endothelial cells expressed more VCAM-1 following inflammatory stimulation (P<0.001) (Figure 8B/C), whereas VCAM-1 KO cells did not express 352 353 VCAM-1, confirming successful CRISPR-Cas9 base editing in endothelial cells. 354 VCAM-1 KO cells released EC-EV under basal conditions similar to WT cells (Figure 355 **8D/E)** but VCAM-1 KO endothelial cells did not release more EVs following inflammatory stimulation with TNF- $\alpha$  (Figure 8D/E). WT and VCAM-1 KO EC-EV 356 357 were positive for EV-markers TSG101 and CD9 but only WT inflammatory derived 358 EC-EVs were positive for VCAM-1 (Figure 8F). EC-EVs derived from either TNF- $\alpha$ activated WT or TNF-α activated VCAM-1 KO cells were injected into healthy, wild-359 type mice at the same concentration  $(1 \times 10^9 / \text{mL EC-EVs})$ . Using the miRNA-39-3p 360

labelling technique (described above) we found that VCAM-1 deficient EC-EVs and WT EC-EV accumulate in the spleen at similar levels (**Figure 8G**), but VCAM-1 deficient EC-EVs did not induce alteration in gene expression that were comparable to WT EC-EVs responses in the spleen for *II-6* (P<0.001), *II-1* $\beta$  (P<0.05) and *Cxcl1* (P<0.05) (**Figure 8H**), suggesting alter signalling. Furthermore, deletion of VCAM-1 in EC-EVs prevented mobilisation of splenic neutrophils to peripheral blood when compared to wild-type VCAM-1+ EC-EVs (**Figure 8I and 8J**).

368

## 369 Discussion

370 Mobilisation of neutrophils occurs rapidly after AMI in mice and humans (1, 3, 4) and 371 their number in peripheral blood correlates with the extent of myocardial injury (1-3). 372 The bone marrow has been regarded as the principal source for neutrophils that are 373 mobilised to peripheral blood after injury, because (i) it is the primary site for 374 granulopoiesis (8-10); (ii) it contains ample reserves of mature cells and; (iii) 375 releases neutrophils in response to injection of exogenous chemokines (12-16). 376 However, the divergent timings of neutrophil mobilisation (rapid) (1, 20) and 377 chemokine elevation (delayed) in vivo (17, 18, 43) suggest that additional processes 378 may be involved.

379 Here, we have identified a previously unknown mechanism by which ischemic injury 380 to the myocardium signals to mobilization of neutrophils from a splenic reserve. We 381 show that: (i) EC-EV generated under conditions of inflammation are enriched for 382 VCAM-1, miRNA-126-3p and miRNA-126-5p; (ii) EC-EVs are delivered to the 383 spleen, where they alter gene and protein expression; and (iii) induce the 384 mobilisation of splenic neutrophils to peripheral blood. Notably, (iv) these EC-EV 385 effects are dependent on VCAM-1. Furthermore, (v) we show that neutrophil 386 transcriptomes are differentially regulated following AMI, prior to entry into the 387 myocardium. (vi) Targets of miRNA-126 are significantly altered in neutrophil 388 transcriptomes post-AMI and (vii) administration of miRNA-126 antagomir 389 significantly reduces infarct size in vivo.

Mature neutrophils are held in large numbers in the haemopoietic cords through interactions with the neutrophil receptors CXCR4 and CXCL12 (*11, 44, 45*). Loss of CXCL12 induces an increase in peripheral blood neutrophils. Injection of

393 chemotactic factors (*13*), CXCL chemokines (*12, 14*) and G-CSF (*15, 16*) can drive 394 the rapid mobilisation of neutrophils across the sinusoidal endothelium through 395 alterations in CXCR4-CXCL12.

396 Scrutiny of the relative timings of cytokine elevation after ischaemic injury in relation 397 to neutrophil mobilisation does not support their role in this early mobilisation, since 398 both the onset and peaks in neutrophil mobilisation occur prior to those for cytokine 399 elevation (17, 18, 43). IL-8 injection mobilised neutrophils from the bone marrow 400 (13), but after reperfusion in AMI, even in blood from the coronary sinus (undiluted 401 myocardial effluent), the elevation is modest (0.1-fold) (18, 19). Furthermore, we 402 that the absolute concentration based on these calculate physiological 403 measurements is approximately 2-3 orders of magnitude less than the concentration 404 used to elicit neutrophil mobilisation in mice (14). Finally, neutrophils are the first 405 cells to arrive in the acutely injured tissue. Neutrophil depletion dampens plasma 406 chemokines levels following AMI (7) and in a mouse air pouch model (46). It is not 407 clear which other cells in the profoundly ischaemic myocardium could be capable of 408 the rapid synthesis of chemokines, that would be of sufficient magnitude to mediate 409 neutrophil mobilisation from a remote site such as the bone marrow. The 410 sympathetic nervous system is also activated following AMI and mobilises 411 hematopoietic stem cells (HSCs) from the bone marrow (47). However, HSCs are 412 immature cells unlike terminally differentiated neutrophils and blood numbers of 413 HSCs do not peak until >6 hours post-AMI, subsequent to the increase in peripheral 414 blood neutrophils.

By contrast, numerous studies have shown that hypoxia promotes the rapid (<30 minutes) release of EVs by endothelial cells (*40*). We show that activated endothelial cells in culture liberate large amounts of EV that contain VCAM-1 in their 418 membranes. Using CRISPR/Cas9 genome base editing of cultured endothelial cells, 419 we generatedVCAM-1-deficient EV and showed that while VCAM-1 was not 420 essential for splenic localisation, its absence removed the ability of EV to provoke 421 the rapid mobilisation of neutrophils. Importantly, EVs are taken up rapidly and 422 selectively by the spleen where they become locally concentrated (*24, 48*), unlike 423 chemokines, which have a systemic effect.

424 Following injury to the myocardium there is a marked increase in VCAM-1-bearing-425 EVs. VCAM-1 is a glycoprotein, which is expressed on activated endothelium and 426 has a well-established role in the recruitment of circulating leukocytes by binding 427 integrins (31, 49, 50), including CD49d (51) and CD11b/CD18 (52). Therefore, our 428 findings suggest an efficient signalling system, in which neutrophils are activated and 429 mobilised by engaging VCAM-1-bearing EVs that are taken up in the spleen, having 430 been released remotely from activated endothelium. A subsequent interaction 431 between neutrophils in circulation and static VCAM-1 on activated endothelial cells 432 mediates their recruitment to the original site of injury.

433 The recruitment of neutrophils to the injured myocardium is an essential step in 434 tissue response to injury and repair (1, 7, 20) and thus modulating the neutrophil 435 response raises possibilities for immuno-modulatory interventions in selected 436 inflammatory pathologies, including AMI. Peripheral blood neutrophils are elevated at 437 time of presentation with AMI in patients and rapidly increase in peripheral blood 438 following AMI in mice. Here, we show that splenic-neutrophils are rapidly mobilised to peripheral blood by EC-EV bearing VCAM-1. These findings complement the 439 440 current paradigm in which neutrophils are liberated from bone marrow reserves 441 through elevations in blood chemokines. We demonstrate a novel and efficient 442 signalling mechanism between the injured heart microvasculature and the spleen.

443 Endothelial cells are ideally placed for the rapid release of EVs to peripheral blood 444 during ischemia. EV clearance is rapid and predominately to the spleen, which 445 contains neutrophils in the sup-capsular red pulp. Precisely how neutrophils are 446 retained in the spleen is not known, but our findings suggest that local chemokine 447 signalling may be important, as delivery of endothelial cell derived EVs rich in 448 miRNA-126 downregulates retention chemokines, including the miRNA-126 target 449 CXCL12, and induces expression of neutrophil mobilisation signals, namely CXCL1. 450 Importantly, we show that these processes are dependent on EV-VCAM-1, an 451 integrin with a well-documented role in immune cell recruitment. Furthermore, we 452 make a new observation that peripheral blood neutrophils are transcriptionally 453 activated prior to recruitment to the injured myocardium, with a bias towards miRNA-126-mRNA targets. Our bioinformatics analysis revealed SRP-dependent co-454 455 translational protein targeting to membrane as the most significantly enriched 456 pathway that was conserved between the human and the mouse blood neutrophils 457 following AMI. SRP is necessary for transferring newly synthesised nascent proteins 458 from the ribosome, which are destined for cellular excretion. SRP monoallelic 459 mutations induce a congenital blood neutropenia, possibly due to an increase in 460 susceptibility of neutrophils to apoptosis and the unfolded protein response (53, 54). 461 A significant enrichment for the universally conserved SRP supports our conclusion 462 that neutrophils are transcriptionally active prior to recruitment to the injured heart. 463 Targeting SRP may open novel opportunities to target neutrophil transcriptomes 464 prior to tissue recruitment to modulate their survival, function and phenotype, thereby 465 protecting injured tissues from pro-inflammatory neutrophil mediated damage.

<sup>466</sup> In conclusion, we demonstrate that the injured myocardium can rapidly mobilise <sup>467</sup> splenic neutrophils through generation and release of EC-EVs that bear VCAM-1.

468 These findings provide novel insights into how neutrophils are mobilised to 469 peripheral blood following ischaemic injury, without the need for immediate 470 generation and release of chemokines. EVs are decorated in surface proteins and 471 integrins, which allows them to interact with cells and home to specific sites (55, 56). 472 A functionally efficient reciprocity may operate, in which VCAM-1, on endothelial cell-473 derived EVs is required for the mobilisation of splenic neutrophils, complementing 474 the known role of static VCAM-1 in the recruitment of circulating neutrophils to 475 activated endothelium. Neutrophils are the first cells recruited to the ischemic 476 myocardium and are a major source of chemokines (7). Thus, the well-established 477 mobilisation of neutrophils from bone marrow reserves in response to chemokines 478 (12-16) represent a secondary response, which is consistent with the time course of 479 earlier reports and with our observations that there is no rapid bone marrow 480 mobilisation in the early phase.

We have shown proof of concept that genetic manipulation can alter EV properties in functionally important ways. Immunomodulation of the neutrophil and monocyte response to AMI using EV vectors may provide therapeutic opportunities in AMI.

484

#### 485 Materials and Methods

#### 486 <u>Acute myocardial infarction patients</u>

All clinical investigations were conducted in accordance with the Declaration of Helsinki. The Oxfordshire Research Ethics Committee (references 08/H0603/41 and 11/SC/0397) approved human clinical cohort protocols. All patients provided informed written consent for inclusion in the study.

491

## 492 LAD ligation model

All animal procedures were approved by an ethical review committee at the University of Oxford or NYU Lagone Health. UK experimental interventions were carried out by UK Home Office personal licence holders under the authority of a Home Office project licence.

497

<sup>498</sup> Further experimental details are provided in the supplementary methods.

499

#### 500 Data Availability

RNA Sequencing data are deposited at Gene Expression Omnibus. *Pending* accession number.

503

504 Statistical analysis

All values are group mean  $\pm$  standard deviation (s.d.). Paired and unpaired two-tailed student's t test was used to compare 2 groups, a one-way or two-way analysis of variance (ANOVA) or mixed model effects with post-hoc Bonferroni correction was used to compare multiple group (>2) means with one, two or more independent variables. *p* values <0.05 were considered significant. Hierarchical clustering analysis and generation of heatmap plots was performed using the pheatmap R package v1.0.12.

512

513

514

#### 515 **References**

516	1.	M. J. Schloss, M. Horckmans, K. Nitz, J. Duchene, M. Drechsler, K. Bidzhekov, C.
517		Scheiermann, C. Weber, O. Soehnlein, S. Steffens, The time-of-day of myocardial infarction
518		onset affects healing through oscillations in cardiac neutrophil recruitment. EMBO Mol Med
519		<b>8</b> , 937-948 (2016).

- T. M. Guo, B. Cheng, L. Ke, S. M. Guan, B. L. Qi, W. Z. Li, B. Yang, Prognostic Value of
   Neutrophil to Lymphocyte Ratio for In-hospital Mortality in Elderly Patients with Acute
   Myocardial Infarction. *Curr Med Sci* 38, 354-359 (2018).
- T. Kong, T. H. Kim, Y. S. Park, S. P. Chung, H. S. Lee, J. H. Hong, J. W. Lee,
  J. S. You, I. Park, Usefulness of the delta neutrophil index to predict 30-day
  mortality in patients with ST segment elevation myocardial infarction. *Scientific reports* 7, 15718 (2017).
- G. Sreejit, A. Abdel-Latif, B. Athmanathan, R. Annabathula, A. Dhyani, S. K.
   Noothi, G. A. Quaife-Ryan, A. Al-Sharea, G. Pernes, D. Dragoljevic, H. Lal, K.
   Schroder, B. Y. Hanaoka, C. Raman, M. B. Grant, J. E. Hudson, S. S. Smyth,
   E. R. Porrello, A. J. Murphy, P. R. Nagareddy, Neutrophil-Derived S100A8/A9
   Amplify Granulopoiesis After Myocardial Infarction. *Circulation* 141, 1080 1094 (2020).
- 5. S. Chia, J. T. Nagurney, D. F. Brown, O. C. Raffel, F. Bamberg, F. Senatore,
  F. J. Wackers, I. K. Jang, Association of leukocyte and neutrophil counts with
  infarct size, left ventricular function and outcomes after percutaneous
  coronary intervention for ST-elevation myocardial infarction. *The American journal of cardiology* **103**, 333-337 (2009).
- 6. H. Lorchner, J. Poling, P. Gajawada, Y. Hou, V. Polyakova, S. Kostin, J. M.
  Adrian-Segarra, T. Boettger, A. Wietelmann, H. Warnecke, M. Richter, T.

540	Kubin, I.	Braun,	Myocardial	healing	requires	Reg3beta-dependent
541	accumulati	on of macr	ophages in th	e ischemi	c heart. <i>Na</i>	ture medicine <b>21</b> , 353-
542	362 (2015)					

. . . .

- M. Horckmans, L. Ring, J. Duchene, D. Santovito, M. J. Schloss, M.
  Drechsler, C. Weber, O. Soehnlein, S. Steffens, Neutrophils orchestrate postmyocardial infarction healing by polarizing macrophages towards a reparative
  phenotype. *European Heart Journal* 38, 187-197 (2016).
- 547 8. M. Evrard, I. W. H. Kwok, S. Z. Chong, K. W. W. Teng, E. Becht, J. Chen, J. L. Sieow, H. L. Penny, G. C. Ching, S. Devi, J. M. Adrover, J. L. Y. Li, K. H. 548 Liong, L. Tan, Z. Poon, S. Foo, J. W. Chua, I. H. Su, K. Balabanian, F. 549 Bachelerie, S. K. Biswas, A. Larbi, W. Y. K. Hwang, V. Madan, H. P. Koeffler, 550 S. C. Wong, E. W. Newell, A. Hidalgo, F. Ginhoux, L. G. Ng, Developmental 551 552 Analysis of Bone Marrow Neutrophils Reveals Populations Specialized in Expansion, Trafficking, and Effector Functions. Immunity 48, 364-379 e368 553 554 (2018).
- Y. P. Zhu, L. Padgett, H. Q. Dinh, P. Marcovecchio, A. Blatchley, R. Wu, E.
   Ehinger, C. Kim, Z. Mikulski, G. Seumois, A. Madrigal, P. Vijayanand, C. C.
   Hedrick, Identification of an Early Unipotent Neutrophil Progenitor with Pro tumoral Activity in Mouse and Human Bone Marrow. *Cell Rep* 24, 2329-2341
   e2328 (2018).
- M. Horckmans, M. Bianchini, D. Santovito, R. T. A. Megens, J. Y. Springael, I.
   Negri, M. Vacca, M. Di Eusanio, A. Moschetta, C. Weber, J. Duchene, S.
   Steffens, Pericardial Adipose Tissue Regulates Granulopoiesis, Fibrosis, and
   Cardiac Function After Myocardial Infarction. *Circulation* **137**, 948-960 (2018).

- 11. R. C. Furze, S. M. Rankin, Neutrophil mobilization and clearance in the bone
  marrow. *Immunology* **125**, 281-288 (2008).
- 566 12. C. Martin, P. C. E. Burdon, G. Bridger, J. C. Gutierrez-Ramos, T. J. Williams,
  567 S. M. Rankin, Chemokines acting via CXCR2 and CXCR4 control the release
  568 of neutrophils from the bone marrow and their return following senescence.
- 569 *Immunity* **19**, 583-593 (2003).
- T. Terashima, D. English, J. C. Hogg, S. F. van Eeden, Release of
  polymorphonuclear leukocytes from the bone marrow by interleukin-8. *Blood*92, 1062-1069 (1998).
- 573 14. M. A. Jagels, T. E. Hugli, Neutrophil chemotactic factors promote
  574 leukocytosis. A common mechanism for cellular recruitment from bone
  575 marrow. *Journal of immunology* **148**, 1119-1128 (1992).
- 576 15. C. L. Semerad, F. L. Liu, A. D. Gregory, K. Stumpf, D. C. Link, G-CSF is an
  577 essential regulator of neutrophil trafficking from the bone marrow to the blood.
  578 *Immunity* 17, 413-423 (2002).
- A. Köhler, K. De Filippo, M. Hasenberg, C. van den Brandt, E. Nye, M. P.
  Hosking, T. E. Lane, L. Männ, R. M. Ransohoff, A. E. Hauser, O. Winter, B.
  Schraven, H. Geiger, N. Hogg, M. Gunzer, G-CSF-mediated thrombopoietin
  release triggers neutrophil motility and mobilization from bone marrow via
  induction of Cxcr2 ligands. *Blood* **117**, 4349-4357 (2011).
- A. Deten, H. C. Volz, W. Briest, H. G. Zimmer, Cardiac cytokine expression is
  upregulated in the acute phase after myocardial infarction. Experimental
  studies in rats. *Cardiovascular research* 55, 329-340 (2002).

- 587 18. F. J. Neumann, I. Ott, M. Gawaz, G. Richardt, H. Holzapfel, M. Jochum, A.
  588 Schomig, Cardiac release of cytokines and inflammatory responses in acute
  589 myocardial infarction. *Circulation* **92**, 748-755 (1995).
- N. Marx, F.-J. Neumann, I. Ott, M. Gawaz, W. Koch, T. Pinkau, A. Schömig,
  Induction of Cytokine Expression in Leukocytes in Acute Myocardial
  Infarction. *Journal of the american college of cardiology* **30**, 165-170 (1997).
- M. Horckmans, L. Ring, J. Duchene, D. Santovito, M. J. Schloss, M.
  Drechsler, C. Weber, O. Soehnlein, S. Steffens, Neutrophils orchestrate postmyocardial infarction healing by polarizing macrophages towards a reparative
  phenotype. *Eur Heart J* 38, 187-197 (2017).
- 597 21. I. Puga, M. Cols, C. M. Barra, B. He, L. Cassis, M. Gentile, L. Comerma, A. Chorny, M. Shan, W. Xu, G. Magri, D. M. Knowles, W. Tam, A. Chiu, J. B. 598 599 Bussel, S. Serrano, J. A. Lorente, B. Bellosillo, J. Lloreta, N. Juanpere, F. 600 Alameda, T. Baro, C. D. de Heredia, N. Toran, A. Catala, M. Torrebadell, C. 601 Fortuny, V. Cusi, C. Carreras, G. A. Diaz, J. M. Blander, C. M. Farber, G. Silvestri, C. Cunningham-Rundles, M. Calvillo, C. Dufour, L. D. Notarangelo, 602 V. Lougaris, A. Plebani, J. L. Casanova, S. C. Ganal, A. Diefenbach, J. I. 603 604 Arostegui, M. Juan, J. Yague, N. Mahlaoui, J. Donadieu, K. Chen, A. Cerutti, B cell-helper neutrophils stimulate the diversification and production of 605 606 immunoglobulin in the marginal zone of the spleen. Nat Immunol 13, 170-180 607 (2011).
- J. F. Deniset, B. G. Surewaard, W. Y. Lee, P. Kubes, Splenic Ly6G(high)
  mature and Ly6G(int) immature neutrophils contribute to eradication of S.
  pneumoniae. *J Exp Med* 214, 1333-1350 (2017).

F. K. Swirski, M. Nahrendorf, M. Etzrodt, M. Wildgruber, V. Cortez-Retamozo,
P. Panizzi, J. L. Figueiredo, R. H. Kohler, A. Chudnovskiy, P. Waterman, E.
Aikawa, T. R. Mempel, P. Libby, R. Weissleder, M. J. Pittet, Identification of
splenic reservoir monocytes and their deployment to inflammatory sites. *Science* 325, 612-616 (2009).

- N. Akbar, J. E. Digby, T. J. Cahill, A. N. Tavare, A. L. Corbin, S. Saluja, S.
  Dawkins, L. Edgar, N. Rawlings, K. Ziberna, E. McNeill, S. Oxford Acute
  Myocardial Infarction, E. Johnson, A. A. Aljabali, R. A. Dragovic, M. Rohling,
  T. G. Belgard, I. A. Udalova, D. R. Greaves, K. M. Channon, P. R. Riley, D. C.
  Anthony, R. P. Choudhury, Endothelium-derived extracellular vesicles
  promote splenic monocyte mobilization in myocardial infarction. *JCI Insight* 2,
  7;2(17):e93344 (2017).
- 623 25. C. Thery, K. W. Witwer, E. Aikawa, M. J. Alcaraz, J. D. Anderson, R. Andriantsitohaina, A. Antoniou, T. Arab, F. Archer, G. K. Atkin-Smith, D. C. 624 625 Ayre, J. M. Bach, D. Bachurski, H. Baharvand, L. Balaj, S. Baldacchino, N. N. Bauer, A. A. Baxter, M. Bebawy, C. Beckham, A. Bedina Zavec, A. 626 Benmoussa, A. C. Berardi, P. Bergese, E. Bielska, C. Blenkiron, S. Bobis-627 Wozowicz, E. Boilard, W. Boireau, A. Bongiovanni, F. E. Borras, S. Bosch, C. 628 M. Boulanger, X. Breakefield, A. M. Breglio, M. A. Brennan, D. R. Brigstock, 629 A. Brisson, M. L. Broekman, J. F. Bromberg, P. Bryl-Gorecka, S. Buch, A. H. 630 631 Buck, D. Burger, S. Busatto, D. Buschmann, B. Bussolati, E. I. Buzas, J. B. Byrd, G. Camussi, D. R. Carter, S. Caruso, L. W. Chamley, Y. T. Chang, C. 632 Chen, S. Chen, L. Cheng, A. R. Chin, A. Clayton, S. P. Clerici, A. Cocks, E. 633 634 Cocucci, R. J. Coffey, A. Cordeiro-da-Silva, Y. Couch, F. A. Coumans, B. 635 Coyle, R. Crescitelli, M. F. Criado, C. D'Souza-Schorey, S. Das, A. Datta

636	Chaudhuri, P. de Candia, E. F. De Santana, O. De Wever, H. A. Del Portillo,
637	T. Demaret, S. Deville, A. Devitt, B. Dhondt, D. Di Vizio, L. C. Dieterich, V.
638	Dolo, A. P. Dominguez Rubio, M. Dominici, M. R. Dourado, T. A. Driedonks,
639	F. V. Duarte, H. M. Duncan, R. M. Eichenberger, K. Ekstrom, S. El
640	Andaloussi, C. Elie-Caille, U. Erdbrugger, J. M. Falcon-Perez, F. Fatima, J. E.
641	Fish, M. Flores-Bellver, A. Forsonits, A. Frelet-Barrand, F. Fricke, G.
642	Fuhrmann, S. Gabrielsson, A. Gamez-Valero, C. Gardiner, K. Gartner, R.
643	Gaudin, Y. S. Gho, B. Giebel, C. Gilbert, M. Gimona, I. Giusti, D. C.
644	Goberdhan, A. Gorgens, S. M. Gorski, D. W. Greening, J. C. Gross, A.
645	Gualerzi, G. N. Gupta, D. Gustafson, A. Handberg, R. A. Haraszti, P.
646	Harrison, H. Hegyesi, A. Hendrix, A. F. Hill, F. H. Hochberg, K. F. Hoffmann,
647	B. Holder, H. Holthofer, B. Hosseinkhani, G. Hu, Y. Huang, V. Huber, S. Hunt,
648	A. G. Ibrahim, T. Ikezu, J. M. Inal, M. Isin, A. Ivanova, H. K. Jackson, S.
649	Jacobsen, S. M. Jay, M. Jayachandran, G. Jenster, L. Jiang, S. M. Johnson,
650	J. C. Jones, A. Jong, T. Jovanovic-Talisman, S. Jung, R. Kalluri, S. I. Kano, S.
651	Kaur, Y. Kawamura, E. T. Keller, D. Khamari, E. Khomyakova, A. Khvorova,
652	P. Kierulf, K. P. Kim, T. Kislinger, M. Klingeborn, D. J. Klinke, 2nd, M. Kornek,
653	M. M. Kosanovic, A. F. Kovacs, E. M. Kramer-Albers, S. Krasemann, M.
654	Krause, I. V. Kurochkin, G. D. Kusuma, S. Kuypers, S. Laitinen, S. M.
655	Langevin, L. R. Languino, J. Lannigan, C. Lasser, L. C. Laurent, G. Lavieu, E.
656	Lazaro-Ibanez, S. Le Lay, M. S. Lee, Y. X. F. Lee, D. S. Lemos, M. Lenassi,
657	A. Leszczynska, I. T. Li, K. Liao, S. F. Libregts, E. Ligeti, R. Lim, S. K. Lim, A.
658	Line, K. Linnemannstons, A. Llorente, C. A. Lombard, M. J. Lorenowicz, A. M.
659	Lorincz, J. Lotvall, J. Lovett, M. C. Lowry, X. Loyer, Q. Lu, B. Lukomska, T. R.
660	Lunavat, S. L. Maas, H. Malhi, A. Marcilla, J. Mariani, J. Mariscal, E. S.

661	Martens-Uzunova, L. Martin-Jaular, M. C. Martinez, V. R. Martins, M. Mathieu,
662	S. Mathivanan, M. Maugeri, L. K. McGinnis, M. J. McVey, D. G. Meckes, Jr.,
663	K. L. Meehan, I. Mertens, V. R. Minciacchi, A. Moller, M. Moller Jorgensen, A.
664	Morales-Kastresana, J. Morhayim, F. Mullier, M. Muraca, L. Musante, V.
665	Mussack, D. C. Muth, K. H. Myburgh, T. Najrana, M. Nawaz, I. Nazarenko, P.
666	Nejsum, C. Neri, T. Neri, R. Nieuwland, L. Nimrichter, J. P. Nolan, E. N. Nolte-
667	't Hoen, N. Noren Hooten, L. O'Driscoll, T. O'Grady, A. O'Loghlen, T. Ochiya,
668	M. Olivier, A. Ortiz, L. A. Ortiz, X. Osteikoetxea, O. Ostergaard, M. Ostrowski,
669	J. Park, D. M. Pegtel, H. Peinado, F. Perut, M. W. Pfaffl, D. G. Phinney, B. C.
670	Pieters, R. C. Pink, D. S. Pisetsky, E. Pogge von Strandmann, I.
671	Polakovicova, I. K. Poon, B. H. Powell, I. Prada, L. Pulliam, P. Quesenberry,
672	A. Radeghieri, R. L. Raffai, S. Raimondo, J. Rak, M. I. Ramirez, G. Raposo,
673	M. S. Rayyan, N. Regev-Rudzki, F. L. Ricklefs, P. D. Robbins, D. D. Roberts,
674	S. C. Rodrigues, E. Rohde, S. Rome, K. M. Rouschop, A. Rughetti, A. E.
675	Russell, P. Saa, S. Sahoo, E. Salas-Huenuleo, C. Sanchez, J. A. Saugstad,
676	M. J. Saul, R. M. Schiffelers, R. Schneider, T. H. Schoyen, A. Scott, E.
677	Shahaj, S. Sharma, O. Shatnyeva, F. Shekari, G. V. Shelke, A. K. Shetty, K.
678	Shiba, P. R. Siljander, A. M. Silva, A. Skowronek, O. L. Snyder, 2nd, R. P.
679	Soares, B. W. Sodar, C. Soekmadji, J. Sotillo, P. D. Stahl, W. Stoorvogel, S.
680	L. Stott, E. F. Strasser, S. Swift, H. Tahara, M. Tewari, K. Timms, S. Tiwari, R.
681	Tixeira, M. Tkach, W. S. Toh, R. Tomasini, A. C. Torrecilhas, J. P. Tosar, V.
682	Toxavidis, L. Urbanelli, P. Vader, B. W. van Balkom, S. G. van der Grein, J.
683	Van Deun, M. J. van Herwijnen, K. Van Keuren-Jensen, G. van Niel, M. E.
684	van Royen, A. J. van Wijnen, M. H. Vasconcelos, I. J. Vechetti, Jr., T. D. Veit,
685	L. J. Vella, E. Velot, F. J. Verweij, B. Vestad, J. L. Vinas, T. Visnovitz, K. V.

686		Vukman, J. Wahlgren, D. C. Watson, M. H. Wauben, A. Weaver, J. P.
687		Webber, V. Weber, A. M. Wehman, D. J. Weiss, J. A. Welsh, S. Wendt, A. M.
688		Wheelock, Z. Wiener, L. Witte, J. Wolfram, A. Xagorari, P. Xander, J. Xu, X.
689		Yan, M. Yanez-Mo, H. Yin, Y. Yuana, V. Zappulli, J. Zarubova, V. Zekas, J. Y.
690		Zhang, Z. Zhao, L. Zheng, A. R. Zheutlin, A. M. Zickler, P. Zimmermann, A.
691		M. Zivkovic, D. Zocco, E. K. Zuba-Surma, Minimal information for studies of
692		extracellular vesicles 2018 (MISEV2018): a position statement of the
693		International Society for Extracellular Vesicles and update of the MISEV2014
694		guidelines. J Extracell Vesicles 7, 1535750 (2018).
695	26.	N. Akbar, V. Azzimato, R. P. Choudhury, M. Aouadi, Extracellular vesicles in
696		metabolic disease. Diabetologia 62, 2179-2187 (2019).
697	27.	J. P. G. Sluijter, S. M. Davidson, C. M. Boulanger, E. I. Buzás, D. P. V. de
698		Kleijn, F. B. Engel, Z. Giricz, D. J. Hausenloy, R. Kishore, S. Lecour, J. Leor,
699		R. Madonna, C. Perrino, F. Prunier, S. Sahoo, R. M. Schiffelers, R. Schulz, L.
700		W. Van Laake, K. Ytrehus, P. Ferdinandy, Extracellular vesicles in diagnostics
701		and therapy of the ischaemic heart: Position Paper from the Working Group
702		on Cellular Biology of the Heart of the European Society of Cardiology.
703		Cardiovascular research <b>114</b> , 19-34 (2018).
704	28.	A. E. Russell, A. Sneider, K. W. Witwer, P. Bergese, S. N. Bhattacharyya, A.
705		Cocks, E. Cocucci, U. Erdbrugger, J. M. Falcon-Perez, D. W. Freeman, T. M.
706		Gallagher, S. Hu, Y. Huang, S. M. Jay, S. I. Kano, G. Lavieu, A. Leszczynska,
707		A. M. Llorente, Q. Lu, V. Mahairaki, D. C. Muth, N. Noren Hooten, M.
708		Ostrowski, I. Prada, S. Sahoo, T. H. Schoyen, L. Sheng, D. Tesch, G. Van
709		Niel, R. E. Vandenbroucke, F. J. Verweij, A. V. Villar, M. Wauben, A. M.
710		Wehman, H. Yin, D. R. F. Carter, P. Vader, Biological membranes in EV

711	biogenesis, stability, uptake, and cargo transfer: an ISEV position paper
712	arising from the ISEV membranes and EVs workshop. J Extracell Vesicles 8,
713	1684862 (2019).

- X. Loyer, I. Zlatanova, C. Devue, M. Yin, K. Y. Howangyin, P. Klaihmon, C. L.
  Guerin, M. Kheloufi, J. Vilar, K. Zannis, B. K. Fleischmann, D. W. Hwang, J.
  Park, H. Lee, P. Menasche, J. S. Silvestre, C. M. Boulanger, Intra-Cardiac
  Release of Extracellular Vesicles Shapes Inflammation Following Myocardial
  Infarction. *Circulation research* **123**, 100-106 (2018).
- 30. M. Cheng, J. Yang, X. Zhao, E. Zhang, Q. Zeng, Y. Yu, L. Yang, B. Wu, G. Yi, 719 720 X. Mao, K. Huang, N. Dong, M. Xie, N. A. Limdi, S. D. Prabhu, J. Zhang, G. Qin, Circulating myocardial microRNAs from infarcted hearts are carried in 721 mobilise progenitor 722 exosomes and bone marrow cells. Nature 723 communications 10, 959 (2019).
- 31. E. A. Ross, M. R. Douglas, S. H. Wong, E. J. Ross, S. J. Curnow, G. B. Nash,
  E. Rainger, D. Scheel-Toellner, J. M. Lord, M. Salmon, C. D. Buckley,
  Interaction between integrin alpha9beta1 and vascular cell adhesion
  molecule-1 (VCAM-1) inhibits neutrophil apoptosis. *Blood* 107, 1178-1183
  (2006).
- N. Ruparelia, J. E. Digby, A. Jefferson, D. J. Medway, S. Neubauer, C. A.
  Lygate, R. P. Choudhury, Myocardial infarction causes inflammation and
  leukocyte recruitment at remote sites in the myocardium and in the renal
  glomerulus. *Inflamm Res* 62, 515-525 (2013).
- A. M. Akhtar, J. E. Schneider, S. J. Chapman, A. Jefferson, J. E. Digby, K.
  Mankia, Y. Chen, M. A. McAteer, K. J. Wood, R. P. Choudhury, In vivo
  quantification of VCAM-1 expression in renal ischemia reperfusion injury using

- non-invasive magnetic resonance molecular imaging. *PloS one* 5, e12800
  (2010).
- L. Osborn, C. Hession, R. Tizard, C. Vassallo, S. Luhowskyj, G. Chirosso, R.
  Lobb, Direct Expression Cloning of Vascular Cell-Adhesion Molecule-1, a
  Cytokine-Induced Endothelial Protein That Binds to Lymphocytes. *Cell* 59, 1203-1211 (1989).
- 742 35. V. Agarwal, G. W. Bell, J. W. Nam, D. P. Bartel, Predicting effective 743 microRNA target sites in mammalian mRNAs. *Elife* **4**, (2015).
- 36. C. Sticht, C. De La Torre, A. Parveen, N. Gretz, miRWalk: An online resource
  for prediction of microRNA binding sites. *PloS one* **13**, e0206239 (2018).
- 746 37. W. Liu, X. Wang, Prediction of functional microRNA targets by integrative
  747 modeling of microRNA binding and target expression data. *Genome Biol* 20,
  748 18 (2019).
- 38. B. Jassal, L. Matthews, G. Viteri, C. Gong, P. Lorente, A. Fabregat, K.
  Sidiropoulos, J. Cook, M. Gillespie, R. Haw, F. Loney, B. May, M. Milacic, K.
  Rothfels, C. Sevilla, V. Shamovsky, S. Shorser, T. Varusai, J. Weiser, G. Wu,
  L. Stein, H. Hermjakob, P. D'Eustachio, The reactome pathway
  knowledgebase. *Nucleic acids research* 48, D498-D503 (2019).
- 39. E. Vafadarnejad, G. Rizzo, L. Krampert, P. Arampatzi, A. P. Arias-Loza, Y.
  Nazzal, A. Rizakou, T. Knochenhauer, S. R. Bandi, V. A. Nugroho, D. J. J.
  Schulz, M. Roesch, P. Alayrac, J. Vilar, J. S. Silvestre, A. Zernecke, A. E.
  Saliba, C. Cochain, Dynamics of Cardiac Neutrophil Diversity in Murine
- 758 Myocardial Infarction. *Circulation research* **127**, e232-e249 (2020).

40. S. M. Davidson, J. A. Riquelme, Y. Zheng, J. M. Vicencio, S. Lavandero, D.

- 760 M. Yellon, Endothelial cells release cardioprotective exosomes that may 761 contribute to ischaemic preconditioning. *Scientific reports* **8**, 15885 (2018).
- 41. E. Arner, N. Mejhert, A. Kulyte, P. J. Balwierz, M. Pachkov, M. Cormont, S.
  Lorente-Cebrian, A. Ehrlund, J. Laurencikiene, P. Heden, K. Dahlman-Wright,
- J. F. Tanti, Y. Hayashizaki, M. Ryden, I. Dahlman, E. van Nimwegen, C. O.
- Daub, P. Arner, Adipose tissue microRNAs as regulators of CCL2 production
  in human obesity. *Diabetes* 61, 1986-1993 (2012).
- J. Agudo, A. Ruzo, N. Tung, H. Salmon, M. Leboeuf, D. Hashimoto, C.
  Becker, L. A. Garrett-Sinha, A. Baccarini, M. Merad, B. D. Brown, The miR126-VEGFR2 axis controls the innate response to pathogen-associated
  nucleic acids. *Nat Immunol* **15**, 54-62 (2014).
- V. Rusinkevich, Y. Huang, Z.-y. Chen, W. Qiang, Y.-g. Wang, Y.-f. Shi, H.-t.
  Yang, Temporal dynamics of immune response following prolonged
  myocardial ischemia/reperfusion with and without cyclosporine A. *Acta Pharmacologica Sinica* 40, 1168-1183 (2019).
- K. J. Eash, J. M. Means, D. W. White, D. C. Link, CXCR4 is a key regulator of
  neutrophil release from the bone marrow under basal and stress
  granulopoiesis conditions. *Blood* **113**, 4711-4719 (2009).
- 45. B. T. Suratt, J. M. Petty, S. K. Young, K. C. Malcolm, J. G. Lieber, J. A. Nick,
  J. A. Gonzalo, P. M. Henson, G. S. Worthen, Role of the CXCR4/SDF-1
  chemokine axis in circulating neutrophil homeostasis. *Blood* 104, 565-571
  (2004).
- 46. E. Garcia-Ramallo, T. Marques, N. Prats, J. Beleta, S. L. Kunkel, N.
  Godessart, Resident cell chemokine expression serves as the major

784 mechanism for leukocyte recruitment during local inflammation. *J Immunol*785 **169**, 6467-6473 (2002).

786	47.	P. Dutta, G. Courties, Y. Wei, F. Leuschner, R. Gorbatov, C. S. Robbins, Y.
787		Iwamoto, B. Thompson, A. L. Carlson, T. Heidt, M. D. Majmudar, F.
788		Lasitschka, M. Etzrodt, P. Waterman, M. T. Waring, A. T. Chicoine, A. M. van
789		der Laan, H. W. Niessen, J. J. Piek, B. B. Rubin, J. Butany, J. R. Stone, H. A.
790		Katus, S. A. Murphy, D. A. Morrow, M. S. Sabatine, C. Vinegoni, M. A.
791		Moskowitz, M. J. Pittet, P. Libby, C. P. Lin, F. K. Swirski, R. Weissleder, M.
792		Nahrendorf, Myocardial infarction accelerates atherosclerosis. Nature 487,
793		325-329 (2012).
794	48.	S. C. Saunderson, A. C. Dunn, P. R. Crocker, A. D. McLellan, CD169
795		mediates the capture of exosomes in spleen and lymph node. Blood 123, 208-
796		216 (2014).
797	49.	J. V. Forrester, J. M. Lackie, Adhesion of neutrophil leucocytes under
797 798	49.	J. V. Forrester, J. M. Lackie, Adhesion of neutrophil leucocytes under conditions of flow. <i>Journal of cell science</i> <b>70</b> , 93-110 (1984).
	49. 50.	
798		conditions of flow. Journal of cell science 70, 93-110 (1984).
798 799		conditions of flow. <i>Journal of cell science</i> <b>70</b> , 93-110 (1984). Y. Taooka, J. Chen, T. Yednock, D. Sheppard, The integrin alpha9beta1
798 799 800		conditions of flow. <i>Journal of cell science</i> <b>70</b> , 93-110 (1984). Y. Taooka, J. Chen, T. Yednock, D. Sheppard, The integrin alpha9beta1 mediates adhesion to activated endothelial cells and transendothelial
798 799 800 801		<ul> <li>conditions of flow. <i>Journal of cell science</i> 70, 93-110 (1984).</li> <li>Y. Taooka, J. Chen, T. Yednock, D. Sheppard, The integrin alpha9beta1 mediates adhesion to activated endothelial cells and transendothelial neutrophil migration through interaction with vascular cell adhesion molecule-</li> </ul>
798 799 800 801 802	50.	conditions of flow. <i>Journal of cell science</i> <b>70</b> , 93-110 (1984). Y. Taooka, J. Chen, T. Yednock, D. Sheppard, The integrin alpha9beta1 mediates adhesion to activated endothelial cells and transendothelial neutrophil migration through interaction with vascular cell adhesion molecule- 1. <i>The Journal of cell biology</i> <b>145</b> , 413-420 (1999).
798 799 800 801 802 803	50.	<ul> <li>conditions of flow. <i>Journal of cell science</i> 70, 93-110 (1984).</li> <li>Y. Taooka, J. Chen, T. Yednock, D. Sheppard, The integrin alpha9beta1 mediates adhesion to activated endothelial cells and transendothelial neutrophil migration through interaction with vascular cell adhesion molecule-</li> <li>1. <i>The Journal of cell biology</i> 145, 413-420 (1999).</li> <li>T. B. Issekutz, M. Miyasaka, A. C. Issekutz, Rat blood neutrophils express</li> </ul>
798 799 800 801 802 803 803	50.	<ul> <li>conditions of flow. <i>Journal of cell science</i> 70, 93-110 (1984).</li> <li>Y. Taooka, J. Chen, T. Yednock, D. Sheppard, The integrin alpha9beta1 mediates adhesion to activated endothelial cells and transendothelial neutrophil migration through interaction with vascular cell adhesion molecule- 1. <i>The Journal of cell biology</i> 145, 413-420 (1999).</li> <li>T. B. Issekutz, M. Miyasaka, A. C. Issekutz, Rat blood neutrophils express very late antigen 4 and it mediates migration to arthritic joint and dermal</li> </ul>

808 activation antigen-4 integrins suppresses neutrophil and T-lymphocyte

migration to the joints and improves clinical disease. *Immunology* 88, 569-576
(1996).

- 53. C. Bellanné-Chantelot, B. Schmaltz-Panneau, C. Marty, O. Fenneteau, I. 811 Callebaut, S. Clauin, A. Docet, G.-L. Damaj, T. Leblanc, I. Pellier, C. Stoven, 812 S. Souquere, I. Antony-Debré, B. Beaupain, N. Aladjidi, V. Barlogis, F. 813 814 Bauduer, P. Bensaid, O. Boespflug-Tanguy, C. Berger, Y. Bertrand, L. Carausu, C. Fieschi, C. Galambrun, A. Schmidt, H. Journel, F. Mazingue, B. 815 Nelken, T. C. Quah, E. Oksenhendler, M. Ouachée, M. Pasquet, V. Saada, F. 816 Suarez, G. Pierron, W. Vainchenker, I. Plo, J. Donadieu, Mutations in the 817 818 SRP54 gene cause severe congenital neutropenia as well as Shwachman-819 Diamond-like syndrome. *Blood* **132**, 1318-1331 (2018).
- Y. Mizoguchi, S. Hesse, M. Linder, N. Zietara, M. Lyszkiewicz, Y. Liu, M.
  Tatematsu, P. Grabowski, K. Ahomaa, T. Jeske, S. Hollizeck, E. Rusha, M. K.
  Saito, M. Kobayashi, Z. Alizadeh, Z. Pourpak, S. Iurian, N. Rezaei, E. Unal,
  M. Drukker, B. Walzog, F. Hauck, J. Rappsilber, C. Klein, Defects in Signal
  Recognition Particle (SRP) Components Reveal an Essential and NonRedundant Role for Granule Biogenesis and Differentiation of Neutrophil
  Granulocytes. *Blood* 134, 216-216 (2019).
- A. Hoshino, B. Costa-Silva, T. L. Shen, G. Rodrigues, A. Hashimoto, M. Tesic
  Mark, H. Molina, S. Kohsaka, A. Di Giannatale, S. Ceder, S. Singh, C.
  Williams, N. Soplop, K. Uryu, L. Pharmer, T. King, L. Bojmar, A. E. Davies, Y.
  Ararso, T. Zhang, H. Zhang, J. Hernandez, J. M. Weiss, V. D. Dumont-Cole,
  K. Kramer, L. H. Wexler, A. Narendran, G. K. Schwartz, J. H. Healey, P.
  Sandstrom, K. J. Labori, E. H. Kure, P. M. Grandgenett, M. A. Hollingsworth,
  M. de Sousa, S. Kaur, M. Jain, K. Mallya, S. K. Batra, W. R. Jarnagin, M. S.

834		Brady, O. Fodstad, V. Muller, K. Pantel, A. J. Minn, M. J. Bissell, B. A. Garcia,
835		Y. Kang, V. K. Rajasekhar, C. M. Ghajar, I. Matei, H. Peinado, J. Bromberg,
836		D. Lyden, Tumour exosome integrins determine organotropic metastasis.
837		Nature <b>527</b> , 329-335 (2015).
838	56.	G. Rodrigues, A. Hoshino, C. M. Kenific, I. R. Matei, L. Steiner, D. Freitas, H.
839		S. Kim, P. R. Oxley, I. Scandariato, I. Casanova-Salas, J. Dai, C. R. Badwe,
840		B. Gril, M. Tesic Mark, B. D. Dill, H. Molina, H. Zhang, A. Benito-Martin, L.
841		Bojmar, Y. Ararso, K. Offer, Q. LaPlant, W. Buehring, H. Wang, X. Jiang, T.
842		M. Lu, Y. Liu, J. K. Sabari, S. J. Shin, N. Narula, P. S. Ginter, V. K.
843		Rajasekhar, J. H. Healey, E. Meylan, B. Costa-Silva, S. E. Wang, S. Rafii, N.
844		K. Altorki, C. M. Rudin, D. R. Jones, P. S. Steeg, H. Peinado, C. M. Ghajar, J.
845		Bromberg, M. de Sousa, D. Pisapia, D. Lyden, Tumour exosomal CEMIP
846		protein promotes cancer cell colonization in brain metastasis. Nat Cell Biol 21,
847		1403-1412 (2019).

848

849

## 850 Acknowledgments

# 851 Statement of Contribution

NA isolated, characterized, and utilized EVs in the described experiments and performed western blots, RT-qPCR, chemokine arrays, analysis of infarcted hearts and assisted with *in silico* bioinformatics. ATB, CL, EL, LE, GM, EM, CvS assisted with experimentation. EEC, GJK and CvS undertook antagomiR experiments. ATB performed bioinformatics analysis and generated transcriptome analysis graphs and heat maps. ALC and DP prepared and analysed flow cytometry preparations. AC,

RD and EJ imaged EVs by TEM /Cryo-TEM. MGH performed some AMI surgeries.
TK and CB performed RNA sequencing. JR performed CRISPR-cas9 base editing of
endothelial cells. KJM, PR, KM and DCA led animal investigations. RC and KMC led
human AMI investigations. NA and RC conceived the study. All authors participated
in study design, coordination and helped to draft the manuscript. All authors have
seen the final version of the manuscript and approve of its submission.

864

865 The authors thank the staff at the Oxford Heart Centre for the clinical care of patients 866 recruited in the coordination of the OxAMI study. Phil Townsend and Steve 867 Woodhouse are gratefully acknowledged for general laboratory management. The 868 authors thank biomedical services staff for their expert care of mice used in this 869 study. The OxAMI study is supported by the British Heart Foundation (BHF; grant 870 CH/16/1/32013 to KMC), the BHF Centre of Research Excellence, Oxford 871 (RG/13/1/30181), the National Institute for Health Research Biomedical Research 872 Centre, Oxford and the and the Biomedical Sequencing Facility (BSF) at CeMM for 873 assistance with next-generation sequencing. See Supplemental Acknowledgments 874 for OxAMI details.

875

#### 876 **Funding**

877 NA and RC acknowledge support by research grants from the British Heart 878 Foundation (BHF) Centre of Research Excellence, Oxford (NA and RC: 879 RE/13/1/30181), British Heart Foundation Project Grant (NA and RC: 880 PG/18/53/33895), the Tripartite Immunometabolism Consortium, Novo Nordisk 881 Foundation (RC: NNF15CC0018486), Oxford Biomedical Research Centre (BRC),

882	Nuffield	Benefactio	on for Me	edicine	and the We	Ilcome Institu	utiona	I Strategic	Support
883	Fund	(ISSF)	(NA),	the	National	Institutes	of	Health	(NIHR)
884	(R35HL1	135799,P0	1HL1314	78 (KJ	M) and T32	HL098129 (0	CvS))	and the A	Merican
885	Heart As	ssociation	(19CDA3	3463000	066 (CvS)).	DRFC and G	M ac	knowledge	BBSRC
886	(BB/P00	6205/1). T	he views	expres	sed are thos	e of the auth	or(s) a	and not ne	cessarily
887	those of	the NHS,	the NIHR	or the	Department	of Health			

## 889 **Figures and Figure Legends**

890 Figure 1. Human peripheral blood neutrophils correlate with the extent of 891 myocardial injury in AMI. A Pearson's correlation of peripheral blood neutrophil number (10<sup>9</sup> / L) in patients experiencing AMI significantly correlated with the extent 892 893 of myocardial injury (T2-weight MRI) and **B** LGE MRI 6-months post-AMI (n = 15). **C** 894 Schematic representation of mouse AMI and tissue harvesting for flow cytometry. D 895 Percentage of neutrophils in peripheral blood, spleen, bone marrow and heart 2 896 hours after AMI relative to the levels of intact controls (controls n = 4, AMI n = 3). E 897 Mean fluorescence intensity (MFI) of CD62L/L-selectin on neutrophils in peripheral blood, spleen, bone marrow and heart 2 hours after AMI relative to the levels of 898 899 intact controls (controls n = 4, AMI n = 3). F Percentage of monocytes in peripheral 900 blood, spleen, bone marrow and heart 2 hours after AMI relative to the levels of 901 intact controls (controls n = 4, AMI n = 3). Pearson's correlation was used in A and 902 B, dotted lines represent 95% confidence interval and an unpaired t test was used in **D**, **E** and **F** for statistical analysis. Error bars represent mean  $\pm BD **p < 0.01$ , 903 904 \*\*\**p*□<□0.001.

905

907	Figure 2. Plasma extracellular vesicles (EVs) are elevated in peripheral blood
908	following AMI. A Plasma EV number (10 <sup>8</sup> /mL) at time of presentation following
909	AMI and 6 months later in the same patients ( $n = 15$ ). <b>B</b> Size and concentration
910	profile of plasma EVs at time of presentation following AMI and 6 months later in the
911	same patients ( $n = 15$ ). Pearson's correlation of plasma EVs at time of presentation
912	versus: <b>C</b> extent of myocardial injury as determined by T2-weighted MRI, <b>D</b> LGE 6-
913	months post-AMI, <b>E</b> number of peripheral blood neutrophils following AMI ( $10^9$ / L) ( <i>n</i>
914	= 15). A paired t test was used for statistical analysis in A and B. Pearson's
915	correlation was used in C, D and E, dotted lines represent 95% confidence interval
916	for statistical analysis. ** $p$ < 0.01

918 Figure 3. Human umbilical cord vein endothelial cells (HUVEC) release more 919 extracellular vesicles (EVs) after inflammatory stimulation. A HUVECs: express 920 more VCAM-1 following treatment with recombinant human tumour necrosis factor-α 921  $(TNF-\alpha)$  (10 ng / mL) (n = 9 per group); **B** release more EVs (n = 8 per group). **C** 922 Size and concentration profile of HUVEC derived EVs under basal conditions and 923 after inflammatory stimulation with recombinant human TNF- $\alpha$  (*n* = 8 per group). **D** 924 Transmission electron micrograph (TEM) of HUVEC-derived EVs (scale bar 100 nm) 925 and E cryo-TEM HUVEC-derived EVs (scale bar 50 nm). F Ponceau stain and 926 western blot of HUVEC derived EV from basal and after inflammatory stimulation 927 with TNF- $\alpha$  for eNOS, TSG101, CD9, ATP5A and Histone H3. HUVEC cell pellets 928 (CP), EV-depleted cell culture supernatants (EV-dep) and cell culture media that was 929 not exposed to cells (sham) were used as controls. EC-EV miRNA levels of G hsa-930 miRNA-126-3p and H hsa-miRNA-126-5p under basal conditions and after 931 inflammatory stimulation with TNF- $\alpha$  (*n* = 8 per group). miRNA-126-mRNA targets in 932 human and mouse and their target pathways. I Euler plot of miRNA-126-mRNA targets from TargetScanHuman, TargetScanMouse, miRWalk, miRDB for human 933 934 and the mouse. J Euler plot of Gene Ontology (GO) terms for miRNA-126-mRNA 935 targets for the human and mouse. Shape areas are approximately proportional to 936 number of genes. An unpaired t test was used in A, B, C, G and H for statistical analysis. Error bars represent mean  $\Box \pm SD **p \Box < \Box 0.01, ***p \Box < \Box 0.001.$ 937

939 Figure 4. RNA sequencing of peripheral blood neutrophils following STEMI and 940 NSTEMI patients at the time of presentation versus a control sample obtained from 941 the same patients 1 month post-AMI (n = 3 per group). MA plots shows differential 942 transcriptome at the time of presentation versus a control sample obtained from the 943 same patients 1 month post-AMI in **A** NSTEMI and **B** STEMI patients. Significantly 944 altered genes are highlighted in red. C Euler plot showing similarity and differences 945 in the number of differentially expressed genes in NSTEMI and STEMI patients at 946 time of presentation versus 1 month follow-control samples or between all NSTEMI 947 and all STEMI patients (n = 3 per group). **D** Normalised enrichment scores are 948 shown for significantly enriched Hallmark gene sets from gene set enrichment 949 analysis (GSEA) of presentation versus 1 month follow-control samples from STEMI 950 patients (n = 3). E miRNA-126 antagomiR treatment of wild-type mice prior to 951 induction of AMI. F TTC staining of the myocardium 24 hours post-AMI in scramble 952 and antagomiR treated mice (scramble n = 7 and antagomiR n = 5 per group). 953 Significant differentially expressed (DE) genes in A, B and C were determined by 954 adjusted p-values below the 5% false discovery rate (FDR) threshold. Significantly 955 enriched gene sets in D were defined as having a Benjamini-Hochberg-adjusted 956 p < 0.05. F an unpaired t test was used for analysis. Error bars represent mean  $\Box \pm$  SD 957 \*\**p*□<□0.01.

959 Figure 5 Mouse sEND.1 endothelial cells release more extracellular vesicles 960 (EVs) after inflammatory stimulation. A mouse sEND.1 endothelial cells express 961 more VCAM-1 following treatment with recombinant mouse tumour necrosis factor-α 962 (TNF- $\alpha$ ) (10 ng / mL) (n = 9 per group); **B** release more EVs (n = 11 per group). **C** Size and concentration profile of sEND.1 derived EVs under basal conditions (n = 3)963 and after inflammatory stimulation with recombinant mouse TNF- $\alpha$  (n = 4). D 964 Transmission electron micrograph (TEM) of sEND.1-derived EVs (scale bar 1000 965 966 nm) and E cryo-TEM sEND.1-derived EVs (scale bar 1000 nm). F Ponceau stain and western blot of sEND.1 derived EV from basal and after inflammatory stimulation 967 with TNF-α for ALIX, TSG101, CD9, eNOS, VCAM-1, ATP5A and Histone H3. 968 969 sEND1 cell pellets (CP), EV-depleted cell culture supernatants (EV-dep) and cell 970 culture media that was not exposed to cells (sham) were used as controls. EC-EV 971 miRNA levels of G hsa-miRNA-126-3p and H hsa-miRNA-126-5p under basal 972 conditions (n = 8) and after inflammatory stimulation with TNF- $\alpha$  (n = 7). An unpaired 973 t test was used in A, B, C, G and H for statistical analysis. Error bars represent mean  $\exists \pm \exists SD ** \rho \exists < \exists 0.01, *** \rho \exists < \exists 0.001.$ 974

975

Figure 6. Endothelial cell derived extracellular vesicles (EC-EV) localise to the 977 978 spleen in wild-type, mice and influence gene and protein expression. A RT-979 qPCR detection of EC-EV labelled with miRNA-39-3p in the spleen of mice following intravenous injection of 1 x 10  $^{9}$  EVs by tail vein at 2 (n = 4), 6 (n = 4) and 24 (n = 6) 980 hours post-injection. Sham (n = 10) represents a media only preparation control with 981 982 no EC-EVs. B Heat map showing gene expression in the spleen of mice following intravenous injection of 1 x 10  $^{9}$  EVs by tail vein at 2 (n = 4), 6 (n = 4) and 24 (n = 6) 983 hours post injection. Sham (n = 10) represents a media only preparation control with 984 985 no EC-EVs. Data shown as  $\Delta\Delta$ Ct values normalised to row mean  $\Delta\Delta$ Ct value for 986 each gene. C Heat map showing protein expression in the spleen of mice following intravenous injection of 1 x 10  $^{9}$  EVs by tail vein at 2 hours (*n* = 4) post-injection. 987 988 Sham (n = 4) represents a media only preparation control with no EC-EVs. Data 989 shown are chemokine array dot blot density values normalised to mean row value for 990 each protein. A one-way ANOVA with post-hoc Bonferroni correction was used in A, 991 **B** and an unpaired t test was used in **C**. Error bars represent mean  $\Box \pm$  SD  $\Box$ \*\**p*□<□0.05, \*\**p*□<□0.01, \*\*\**p*□<□0.001. 992

994	Figure 7. Endothelial cell derived extracellular vesicles (EC-EV) (1 x 10 $^9$ EVs /
995	mL) mobilise splenic-neutrophils in healthy mice. A Percentage of neutrophils as
996	a proportion of the total leukocytes (live, CD45 <sup>+</sup> , CD11b <sup>+</sup> , Ly6G <sup>+</sup> ) in peripheral blood,
997	bone marrow and spleen ( $n = 5$ per group). <b>B</b> Splenic-neutrophil mobilisation ratio
998	(peripheral blood neutrophils/ spleen neutrophils) shows net contributions of
999	neutrophil reserves to mobilised peripheral blood neutrophils following intravenous
1000	injections of EC-EV (1 x 10 $^{9}$ EVs m mL) injections ( <i>n</i> = 5 per group). <b>C</b> Mean
1001	fluorescent intensity (MFI) of CD62L/L-selectin on neutrophils in peripheral blood,
1002	spleen and bone marrow 2 hours after ( $n = 5$ per group) intravenous injections of
1003	EC-EV (1 x 10 $^9$ EVs / mL). An unpaired t test was used in A, B and C. Error bars
1004	represent mean $\Box \pm$ SD *** $p \Box < \Box 0.001$ .

1005

1006

Figure 8. Extracellular vesicle (EV) vascular cell adhesion molecule-1 (VCAM-1) 1008 is necessary for endothelial cell (EC)-EV splenic-neutrophil mobilisation. A 1009 Transmission electron micrograph of a VCAM-1+ plasma EV bound to a magnetic 1010 bead of iron oxide (MPIO) conjugated with anti-human VCAM-1 antibodies, scale bar 1011 is 200nm. B/C Western blot of sEND.1 wild-type and CRISPR-cas9 base-edited 1012 VCAM-1 knock outs cell pellets under basal conditions (wild-type n = 4 and VCAM-1 1013 1014 knock out n = 4 per group) and after inflammatory stimulation with recombinant mouse tumour necrosis (TNF- $\alpha$ ). **D** The number of mouse sEND.1 endothelial cell 1015 1016 derived extracellular vesicles (EC-EVs) from wild-type and CRISPR-cas9 baseedited VCAM-1 knock outs under basal conditions (wild-type n = 12 and VCAM-1 1017 knock out n = 11 per group) and after inflammatory stimulation with recombinant 1018 1019 mouse tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ) (*n* = 8 per group). **E** Size and concentration 1020 profile of mouse sEND.1 EC-EVs from wild-type and CRISPR/Cas9 base-edited VCAM-1 knock outs under basal conditions (wild-type n = 12 and VCAM-1 knock out 1021 1022 n = 11 per group) and after inflammatory stimulation with recombinant mouse tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ) (n = 8 per group). **F** Ponceau stain and western blot of 1023 wild-type and CRISPR-case9 base-edited VCAM-1 knock out sEND.1 derived EVs 1024 from basal and after inflammatory stimulation with recombinant mouse TNF-α for 1025 TSG101, CD9 and VCAM-1. Inflammatory stimulated s.END1 cell pellets and EV-1026 depleted cell culture supernatants were used as controls. G RT-gPCR detection of 1027 wild-type sEND.1 and CRISPR-cas9 base-edited VCAM-1 knock outs EC-EV 1028 labelled with miRNA-39-3p in the spleen of mice following intravenous injection of 1 x 1029 1030 10<sup>9</sup> EVs by tail vein at 2 hours post-injection (n = 5 per group). **H** Heat map showing 1031 mRNA expression in the spleen of mice following intravenous injection of wild-type or CRISPR-cas9 base-edited VCAM-1 knock out EC-EVs 1 x 10<sup>9</sup> EVs by tail vein at 2 1032

1033 hours post-injection. Sham represents a media only preparation control with no EC-EVs (*n* = 5 per group). Data shown as  $\Delta\Delta$ Ct values normalised to row mean  $\Delta\Delta$ Ct 1034 value for each gene. I/J Percentage of neutrophils as a proportion of the total 1035 leukocytes (live, CD45<sup>+</sup>, CD11b<sup>+</sup>, Ly6G<sup>+</sup>) in peripheral blood and spleen (sham and 1036 VCAM-1 knock out EC-EV n = 4 and wild-type EC-EV n = 5 per group). I Splenic-1037 neutrophil mobilisation ratio (peripheral blood neutrophils/ spleen neutrophils) shows 1038 1039 net contributions of splenic reserves to mobilised peripheral blood neutrophils following intravenous injections of wild-type or CRISPR-cas9 base-edited VCAM-1 1040 knock out EC-EVs 1 x 10<sup>9</sup> EVs by tail vein at 2 hours post injection. Sham represents 1041 a media only preparation control with no EC-EVs (sham and VCAM-1 knock out EC-1042 1043 EV n = 3 and wild-type EC-EV n = 5 per group). One-way (**H**, **I** and **J**) and two-way 1044 (B, C, D and E) ANOVA with post-hoc Bonferroni correction was used for statistical 1045 analysis. An unpaired t test was used in **F**. Error bars represent mean  $\exists \pm \exists SD$ \* $p \square < \square 0.05$ , \*\* $p \square < \square 0.01$ , \*\*\* $p \square < \square 0.001$ , \*\*\*\* $p \square < \square 0.0001$ . 1046

1048 **Supplementary Table 1** miRNA-126-mRNA targets in the human, mouse and the 1049 overlap between both species.

1050 Supplementary Table 2 miRNA-126-mRNA target pathways using gene ontology
 1051 (GO) in the human, mouse and the overlap between both species.

**Supplementary Table 3** P-values are shown from a Fisher's exact test used to detect enrichment of curated miRNA-126-mRNA targets versus gene sets for neutrophil GO terms.

Supplementary Table 4 GO biological process and Reactome pathway analysis of
 differentially enriched genes in human neutrophils from STEMI patients at the time of
 injury.

**Supplementary Table 5** GO (biological process, molecular function and cellular component) and Reactome pathway analysis in single cell RNA-sequencing of differentially enriched genes in neutrophil blood population 1 follow AMI.

**Supplementary Table 6** GO (biological process, molecular function and cellular component) and Reactome pathway analysis in single cell RNA-sequencing of differentially enriched genes in neutrophil blood population 2 follow AMI.

**Supplementary Table 7** GO (biological process, molecular function and cellular component) and Reactome pathway analysis in single cell RNA-sequencing of differentially enriched genes in neutrophil blood population 3 follow AMI.

**Supplementary Table 8** P-values are shown from a Fisher's exact test used to detect enrichment of differentially enriched genes in human peripheral blood neutrophil versus single cell RNA-sequencing of blood neutrophils from the mouse following AMI.

1071

**Supplementary Table 9** P-values and Jaccard index are shown from a Fisher's exact test used to detect enrichment of differentially enriched gene target pathways using GO (biological process, molecular function and cellular component) and Reactome pathway analysis from human peripheral blood neutrophil versus single cell RNA-sequencing of blood neutrophils from the mouse following AMI.

1077 **Supplementary Table 10** miRNA-126-mRNA targets from the human, mouse and 1078 the overlap (present in human and mouse) were compared with differentially 1079 expressed (DE) genes and the not-DE (NDE) genes in the neutrophil transcriptomes 1080 at time of presentation with AMI.

miRNA-126-mRNA targets from the human, mouse and the overlap (present in
 human and mouse) were compared with differentially expressed (DE) genes and the
 not-DE (NDE) genes in single cell RNA-sequencing of differentially enriched genes
 in neutrophil blood and heart populations following AMI.

1085

Supplementary OxAMI. Author acknowledgments for the Oxford Acute MyocardialInfarction Study.


1088

1089 Supplementary Methods. Details of experimental methods and reagents.


1090

1091 Supplementary uncropped western blots. Unedited images of western blot1092 membranes


(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.




(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.






Scramble AntagomiR

10·

0

hours


(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



A \_\_\_\_\_\_ Áll rights reserved. No reuse allowed without permission. Figure 6


(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

**RT-qPCR** 












Group


Sham


EC-EV












(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

# Figure 7



(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

